Gerresheimer AG GXI

Gerresheimer (ETR:GXI) reported a sequential improvement in preliminary second-quarter 2026 results, with adjusted EBITDA rising more than 50% from the first quarter as operational initiatives began to contribute across all three business segments. Second-quarter revenue totaled €578 million, up fr

Investing.com -- Gerresheimer AG (ETR:GXIG) shares rose on Wednesday after the German pharmaceutical packaging and drug-delivery group reported a sharp sequential improvement in second-quarter adjusted EBITDA and said it expects a stronger second half of 2026.

Election of four shareholder representatives to the Supervisory Board Markus Sieger is new Chairman of the Supervisory Board Course set for debt reduction and comprehensive refinancing DUSSELDORF, GERMANY - September 1, 2026 (NEWMEDIAWIRE) - At ...

Opportunities center on sterile, high-barrier and smart packaging for biologics and injectables; automated production; compliant, traceable formats; and localized manufacturing, diversified sourcing and resilient supply chains. Pharmaceutical Packaging Market Pharmaceutical Packaging Market Dublin, Aug. 31, 2026 (GLOBE NEWSWIRE) -- The "Pharmaceutical Packaging Market Report 2026-2036" report has been added to ResearchAndMarkets.com's offering.This report delivers a thorough examination of the g

Gerresheimer (XTRA:GXI) has moved back into focus after announcing agreements to sell its Centor and Primary Packaging Plastics businesses for about €1.5b, alongside preliminary Q1 2026 results and an ongoing transformation program. Over the past year, Gerresheimer’s total shareholder return fell 38.27%, and longer term performance has also been weak. The 30 day share price return of 5.54% and 7 day share price return of 3.55% indicate that recent momentum has been soft despite the latest...

Gerresheimer AG (GRRMF) reports a mixed Q1 with strong free cash flow improvement and portfolio reshaping, while navigating Moulded Glass weakness and reaffirming full-year guidance.

Gerresheimer (ETR:GXI) reported preliminary first-quarter 2026 results that showed modest revenue growth but lower earnings as the packaging and drug-delivery company prioritized cash preservation, reduced capital spending and limited inventory buildup. Revenue increased by €5 million year over yea

Wolf Lehmann, CFO, and Achim Schalk, Member of the Management Board, Will Assume his Duties Until Further Notice DUSSELDORF, GERMANY - August 24, 2026 (NEWMEDIAWIRE) - Uwe Rohrhoff has stepped down from his role as interim CEO of Gerresheimer AG ...

Gerresheimer Glass Inc. is set to move 139 jobs from its Vineland facility to North Carolina and Mexico starting in 2027.

The sale covers the Centor site in the US and 15 manufacturing locations for primary plastic packaging across nine countries.

The German pharma packaging supplier is offloading some Ohio-based business. The company also announced a few months ago it was shutting down some operations in Illinois.

The new site doubles Gerresheimer’s China capacity for injectable drug packaging.

Approximately 300 jobs for skilled workers from the region Production capacity for primary packaging for injectable pharmaceuticals in China to double 20 years of successful joint venture with Shuangfeng Glass DUESSELDORF, GERMANY and ZHENJIANG...

2025 Results: -31% CO2e, 54% electricity from renewable sources, -63% lost time incident rate Ambitious CO2e reduction target of -52% by 2030 DUSSELDORF, GERMANY - July 9, 2026 (NEWMEDIAWIRE) - Gerresheimer, an innovative systems and solutions ...

The result was affected by non-cash depreciation, amortisation and impairments of around €521.5m ($594.21m), along with restructuring costs.

Revenue of EUR 2.3 billion, adjusted EBITDA of EUR 384 million Organic revenue growth of +0.3%, adjusted EBITDA margin at 16.8% Closing of the sale of Centor and comprehensive debt refinancing planned for this year Implementation of the transform...

Despite a challenging year marked by impairments and operational hurdles, Gerresheimer AG (GRRMF) focuses on transformation and debt refinancing to enhance future profitability.

Gerresheimer (ETR:GXI) said it has completed a broad review of compliance and accounting matters, published its audited 2025 annual report and is now focused on selling Centor, refinancing debt and improving cash generation. Chief Executive Officer Uwe Röhrhoff, who returned to the company in Novem

Newel Health, a company that designs, develops, and operates digital medical devices (SaMD) for life sciences partners, and Gerresheimer, an innovative system and solution provider for drug delivery systems, medical devices, pharmaceutical primary packaging, and digital health solutions, today announced a partnership to support pharmaceutical and biotech companies in developing digital endpoints, digital medical devices, and integrated drug+digital solutions.